Oncology

5 Changes That Should be Made in Oncology

September 25, 2020

COVID-19 is certainly important. But oncologists, people with cancer, and complex ecosystem of cancer care in the U.S. are grappling with other important issues such as reimbursement, distorted incentives, the implications of the massive amount of data that is available, and, of course, high costs and prices. Included are thoughts from five experts on these challenges and how they might be met.

Overcoming Cancer’s Financial Toxicity with Real-World Data

September 15, 2020

Financial Toxicity is a growing concern for many cancer patients and caregivers, and with the continued rise in treatment costs, it can no longer be ignored.

FDA Updates: Treatment for Duchenne Mutation, Gilead Seeks Remdesivir Approval, Data on ALKS 3831

August 16, 2020

Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.

FDA Updates: Assays Used in Cancer Care Get Green Light

August 09, 2020

Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.

Racial Disparities in Cancer Enter the Spotlight

July 29, 2020

Underrepresentation of blacks in clinical trials is garnering special attention.

It's Possible for Those Who Practice, Pay for Precision Oncology to Catch Up to Speed of Innovation

July 14, 2020

The fast-evolving field of precision medicine offers the promise of more effective treatments and better outcomes, and it’s time that we collaborate to keep outdated clinical and reimbursement practices from slowing it down.

David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2

July 01, 2020

In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.